...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity
【24h】

Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity

机译：通过酶联凝集素测定（ELLA）测量的神经氨酸酶抑制抗体滴度的可比性，用于分析流感疫苗免疫原性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuraminidase-inhibition (NI) antibody titers can be used to evaluate the immunogenicity of inactivated influenza vaccines and have provided evidence of serologic cross-reactivity between seasonal and pandemic H1N1 viruses. The traditional thiobarbituric acid assay is impractical for large serologic analyses, and therefore many laboratories use an enzyme-linked lectin assay (ELLA) to determine serum NI antibody titers. The comparability of ELLA NI antibody titers when measured in different laboratories was unknown. Here we report a study conducted through the Consortium for the Standardisation of Influenza SeroEpidemiology (CONSISE) to evaluate the variability of the ELLA. NI antibody titers of a set of 12 samples were measured against both N1 and N2 neuraminidase antigens in 3 independent assays by each of 23 laboratories. For a sample repeated in the same assay, >= 96% of N1 and N2 assays had less than a 4-fold difference in titer. Comparison of the titers measured in assays conducted on 3 different days in the same laboratory showed that a four-fold difference in titer was uncommon. Titers of the same sera measured in different laboratories spanned 3 to 6 two-fold dilutions (i.e., 8-64 fold difference in titer), with an average percent geometric coefficient of variation (%GCV) of 112 and 82% against N1 and N2 antigens, respectively. The difference in titer as indicated by fold range and %GCV was improved by normalizing the NI titers to a standard that was included in each assay. This study identified background signal and the amount of antigen in the assay as critical factors that influence titer, providing important information toward development of a consensus ELLA protocol. Published by Elsevier Ltd.
机译：神经氨酸氨基酶抑制（Ni）抗体滴度可用于评估灭活的流感疫苗的免疫原性，并提供了季节性和大流行H1N1病毒之间的血清学交叉反应性的证据。对于大型血清学分析，传统的硫碱尿酸测定是不切实际的，因此许多实验室使用酶联凝集素测定（OLLLS）来确定血清Ni抗体滴度。在不同实验室测量时Ella Ni抗体滴度的可比性未知。在这里，我们举行通过联盟进行的一项关于流感血型化学的标准化（允许）的标准化进行的研究，以评估ella的可变性。通过23个实验室中的每一个，在3个独立的测定中测量一组12个样品的Ni抗体滴度，测量了N1和N2神经氨酸酶抗原。对于在同一测定中重复的样品，> = 96％的N1和N 2测定具有小于滴度的4倍。在同一实验室3种不同的日期进行的测定中测量的滴度的比较表明，滴度的四倍差异罕见。在不同实验室中测量的相同血清的滴度截止了3至6倍的稀释液（即滴度8-64倍），平均百分比的几何变异系数（％gcv）为112和82％，对N1和N2分别抗原。通过将Ni滴度标准化为每种测定中包括的标准，改善了折叠范围和％GCV的滴度差异。该研究确定了作为影响滴度的关键因素的试验中的背景信号和抗原的量，为艾拉方案的共识，提供了重要信息。 elsevier有限公司出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号